CA266-0001: An open-label two arms randomized Phase 3 study evaluating the efficacy safety of BMS‑986545-01 versus durvalumab in participants with locally advanced unresectable Stage III NSCLC who have not progressed following definitive platinum-based concurrent chemoradiation therapy (ROSETTA Lung-201)
